SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Walker M. Why shark cartilage should succeed against cancer and other pathologies. Medicinal Journalist Report of Innovative Biologics. Townsend Letter for Doctors and Patients. 1991; November: 847854.
  • 2
    Markman M. Shark cartilage: The laetrile of the 1990s [Editorial]. Clev Clin J Med. 1996; 3: 179180.
  • 3
    Pettit GR, Ode RH. Antineoplastic agents: Isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark. J Pharm Sci. 1976; 66: 757758.
  • 4
    Gawler I. You can conquer cancer. Melbourne: Hill of Content Publishing, 1984.
  • 5
    Lee A, Langer R. Shark cartilage contains inhibitors of tumor antigenesis. Science. 1983; 221: 11851187.
  • 6
    Cataldi JM, Osborne DL. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro [Abstract]. FASEB J. 1995; 9: A135.
  • 7
    Sugahara K, Ohi Y, Harada T, de Waard P, Vliegenthart JF. Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate proteoglycans of shark cartilage. I. Six compounds containing 0 or 1 sulfate and/or phosphate residues. J Biol Chem. 1992; 267: 60276035.
  • 8
    de Waard P, Vliegenthart JF, Harada T, Sugahara K. Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate proteoglycans of shark cartilage. II. Seven compounds containing 2 or 3 sulfate residues. J Biol Chem. 1992; 267: 60366043.
  • 9
    Moller HJ, Moller-Pedersen T, Damsgaard TE, Poulsen JH. Demonstration of immunogenic keratan sulphate in commercial chondroitin 6-sulphate from shark cartilage: Implications for ELISA assays. Clin Chim Acta. 1995; 236: 195204.
  • 10
    Gomes EM, Souto PR, Felzenszwalb I. Shark cartilage containing preparation protects cells against hydrogen peroxide induced damage and mutagenesis. Mutat Res. 1996; 367: 204208.
  • 11
    McKinney EC. Proliferation of shark leukocytes [Letter]. In Vitro Cell Dev Biol. 1992; 28A: 303305.
  • 12
    Mathews J. Media feeds frenzy over shark cartilage as cancer treatment [News]. J Natl Cancer Inst. 1993; 85: 11901191.
  • 13
    Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998; 16: 36493655.
  • 14
    Hunt TJ, Connelly JF. Shark cartilage for cancer treatment. Am J Health Syst Pharm. 1995; 52: 17561760.
  • 15
    Lowenthal RM. On eye of newt and bone of shark: the dangers of promoting alternative cancer treatments [Editorial; Comment]. Med J Aust. 1994; 160: 323324.
  • 16
    Blackadar CB. Skeptics of oral administration of shark cartilage [Letter]. Natl Cancer Inst. 1993; 85: 19611962.
  • 17
    Pocock SL, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975; 31: 103115.
  • 18
    Spitzer WO, Dobson AJ, Hall J., et al. Measuring the quality of life of cancer patients. J Chronic Disease. 1981; 34: 585597.
  • 19
    Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998; 16: 36623673.
  • 20
    McCorkle R, Young K.: Development of a symptom distress scale. Cancer Nurs. 1978; 1: 373378.
  • 21
    Sutherland HJ, Walker P, Till JE. The development of a method for determining oncology patients' emotional distress using linear analogue scales. Cancer Nurs. 1988; 5: 303308.
  • 22
    Grunberg SM, Groshen S, Steingass S, Zaretsky S, Meyerowitz B. Comparison of conditional quality of life terminology and visual analogue scale measurements. Qual Life Res. 1996; 5: 6572.
  • 23
    Gudex C, Dolan P, Kind P, Williams A. Health state valuations from the general public using the Visual Analogue Scale. Qual Life Res. 1996; 5: 521531.
  • 24
    Hyland ME, Sodergren SC. Development of a new type of global quality of life scale and comparison and preference for 12 global scales. Qual Life Res. 1996; 5: 469480.
  • 25
    Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther. 1983; 34: 234239.
  • 26
    Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990; 13: 227236.
  • 27
    Lininger LG, Gail MH, Green SB, Byar DP. Comparison of four tests for equality of survival curves in the presence of stratification and censoring. Biometrika. 1979; 66: 419428.
  • 28
    Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med. 1997; 16: 11971209.
  • 29
    Sloan J, Novotny PJ, Loprinzi CL. Analyzing quality-of-life endpoints in clinical trials. SAS Users Group International Proceedings. 1998; 23: 12131222.
  • 30
    Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73: 1322.
  • 31
    Morrison DF. Multivariate statistical methods. New York: McGraw-Hill, 1976.
  • 32
    O'Brien P. Procedures for comparing samples with multiple endpoints. Biometrics. 1984; 40: 10791087.
  • 33
    Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R. Neovastat-a novel antiangiogenic drug for cancer therapy. Anti-Cancer Drugs. 2003; 14: 9196.